The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
Abstract
BACKGROUND AND AIMS A priority is identification of patients with fibrotic nonalcoholic steatohepatitis (Fibro-NASH) defined as NASH with nonalcoholic fatty liver disease activity score ≥ 4 and significant fibrosis (≥ F2). These patients are at highest risk for disease progression and will benefit most from pharmacologic treatment. MRI-based proton density fat fraction (MRI-PDFF) and MR elastography (MRE) risk-stratifies NAFLD patients by assessing steatosis and fibrosis, respectively. We developed a highly specific MRI-based score to identify Fibro-NASH patients. METHODS This analysis included derivation (n=103) and validation (n=244) cohorts from tertiary care centers who underwent MRI, liver biopsy, Transient elastography, and laboratory testing for NAFLD from 2016-2020. To identify Fibro-NASH, a formula was developed based on MRI-PDFF, MRE, and a third variable with highest balanced accuracy per logistic regression. The MRI-AST (MAST) score was created and compared to NAFLD fibrosis (NFS), Fib-4, and FAST scores. RESULTS The MAST score in the validation cohort demonstrated high performance and discrimination [ROC AUC 0.93 (0.88-0.97), 95% CI]. In the validation cohorts, the 90% specificity cutoff of 0.242 corresponded to sensitivity 75.0%, PPV 50.0% and NPV 96.5%, whereas the 90% sensitivity cutoff of 0.165 corresponded to specificity 72.2%, PPV 29.4%, and NPV 98.1%. Compared to NFS and Fib-4, MAST had fewer indeterminate score patients and overall higher AUC. Compared to FAST, MAST exhibited better ROC and overall better discrimination. CONCLUSION The MAST score is an accurate, MRI-serum-based score that outperforms previous scores in noninvasively identifying patients at higher risk of Fibro-NASH. LAY SUMMARY A major priority is identification of patients with nonalcoholic steatohepatitis and significant fibrosis who need treatment and are at risk for clinical liver-related outcomes. We developed a more accurate score using MRI advanced technologies and a laboratory blood test (AST) that outperforms previous non-invasive scores in identifying patients at higher risk of liver disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology · doi:10.1002/hep.30664 · Cited by 390
Self-citationAssociation of histologic disease activity with progression of nonalcoholic fatty liver disease
Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.12565 · Cited by 372
Haldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Harrison, S. A., Gawrieh, S., Roberts, K., Lisanti, C. J., Schwope, R. B., Cebe, K. M., Paradis, V., Bedossa, P., Aldridge Whitehead, J. M., Labourdette, A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.034 · Cited by 293
Self-citation
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Self-citationEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Self-citation
Metadata
- Authors
- Noureddin, M., Truong, E., Gornbein, J. A., Saouaf, R., Guindi, M., Todo, T., Noureddin, N., Yang, J. D., Harrison, S. A., & Alkhouri, N.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 76
- Issue
- 4
- Pages
- 781-787
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3211781776
- Cited by
- 203
- References
- 8
- FWCI
- 18.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. https://app.cochat.ai/papers/10.1016/j.jhep.2021.11.012
- The paper
- Noureddin, M., Truong, E., Gornbein, J. A., Saouaf, R., Guindi, M., Todo, T., Noureddin, N., Yang, J. D., Harrison, S. A., & Alkhouri, N. (2022). MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.11.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.